Q-omics provides the consensus-scored MAPK10 profile across patient tissues and cancer cell-line models. MAPK10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAPK10 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, MAPK10 protein abundance shows 23,244 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where MAPK10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK10 survival associations across molecular data types. MAPK10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK10 RNA expression–survival associations across cancer types. High MAPK10 expression shows unfavorable associations in UVM, but favorable associations in KIRC, HNSC, LGG, PAAD and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAPK10 RNA expression.
This table summarizes MAPK10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MAPK10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK10 shows lower tumor expression in KICH, LUAD, KIRC, COAD, THCA and KIRP. The KICH box plot shows higher MAPK10 RNA expression in normal versus tumor tissue (log2 FC = −2.854, t-test p < 0.001).
This table shows molecular features associated with MAPK10 in patient tissues and cancer cell lines. In patient samples, MAPK10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
